Targeting the HGF/SF receptor c‐met using a hammerhead ribozyme transgene reduces in vitro invasion and migration in prostate cancer cells

No abstract is available for this paper.

• Publication year

  2004

• Venue

  The Prostate

• Publication date

  2004-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/pros.20068PMID 15264243
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Reduction of stromal fibroblast-induced mammary tumor growth, by retroviral ribozyme transgenes to hepatocyte growth factor/scatter factor and its receptor, c-MET.

  2003cited by this paper
• The HGF/SF antagonist NK4 reverses fibroblast‐ and HGF‐induced prostate tumor growth and angiogenesis in vivo

  2003cited by this paper
• Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, a HGF/SF antagonist.

  2003cited by this paper
• Scatter factor-hepatocyte growth factor elevation in the serum of patients with prostate cancer.

  2001influential reference
• Matrilysin mediates extracellular cleavage of E-cadherin from prostate cancer cells: a key mechanism in hepatocyte growth factor/scatter factor-induced cell-cell dissociation and in vitro invasion.

  2001cited by this paper
• A hammerhead ribozyme suppresses expression of hepatocyte growth factor/scatter factor receptor c-MET and reduces migration and invasiveness of breast cancer cells.

  2001cited by this paper
• Adenovirus-mediated ribozyme targeting of HER-2/neu inhibits in vivo growth of breast cancer cells

  2000cited by this paper
• Hepatocyte growth factor secreted by prostate-derived stromal cells stimulates growth of androgen-independent human prostatic carcinoma cells.

  2000cited by this paper
• Induction of apoptosis in oral cancer cells by an anti-bcl-2 ribozyme delivered by an adenovirus vector.

  2000cited by this paper
• Inhibition of HGF/SF-induced breast cancer cell motility and invasion by the HGF/SF variant, NK4

  2000cited by this paper
• Nk4, a new HGF/SF variant, is an antagonist to the influence of HGF/SF on the motility and invasion of colon cancer cells

  2000cited by this paper
• Scatter factor influences the formation of prostate epithelial cell colonies on bone marrow stroma in vitro

  1999cited by this paper
• Hammerhead ribozyme-mediated cleavage of the human insulin-like growth factor-II ribonucleic acid in vitro and in prostate cancer cells.

  1999cited by this paper
• Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression.

  1999influential reference
• Progression-linked overexpression of c-Met in prostatic intraepithelial neoplasia and latent as well as clinical prostate cancers.

  1999cited by this paper
• Hepatocyte growth factor/scatter factor decreases the expression of occludin and transendothelial resistance (TER) and increases paracellular permeability in human vascular endothelial cells

  1999cited by this paper
• ErbB-4 ribozymes abolish neuregulin-induced mitogenesis.

  1998cited by this paper
• Scatter factor stimulates tumor growth and tumor angiogenesis in human breast cancers in the mammary fat pads of nude mice.

  1997cited by this paper
• Inhibition of fibrillin 1 expression using U1 snRNA as a vehicle for the presentation of antisense targeting sequence.

  1997cited by this paper
• HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor

  1997cited by this paper
• Hepatocyte growth factor/scatter factor, a cytokine playing multiple and converse roles.

  1997cited by this paper
• Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma.

  1995cited by this paper
• c-met proto-oncogene expression in benign and malignant human prostate tissues.

  1995cited by this paper
• Hepatocytes and scatter factor

  1990cited by this paper
• Molecular cloning and expression of human hepatocyte growth factor

  1989cited by this paper
• Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

  1987cited by this paper

• Predictive potential of hepatocyte growth factor and bone morphogenetic proteins in lymphatic metastasis of breast cancer

  2025cites this paper
• Transcriptomic Signature and Growth Factor Regulation of Castration-Tolerant Prostate Luminal Progenitor Cells

  2022cites this paper
• Phase II Study of Cabozantinib in Patients With Bone Metastasis

  2022cites this paper
• Resveratrol Suppresses Prostate Cancer Epithelial Cell Scatter/Invasion by Targeting Inhibition of Hepatocyte Growth Factor (HGF) Secretion by Prostate Stromal Cells and Upregulation of E-cadherin by Prostate Cancer Epithelial Cells

  2020cites this paper
• Curcumin inhibits epithelial-mesenchymal transition in oral cancer cells via c-Met blockade.

  2020cites this paper
• Growth factors involve in cellular proliferation, differentiation and migration during prostate cancer metastasis.

  2019cites this paper
• Increased ARF 6 activation correlates with HGF stimulation in non-invasive prostate cancer cells

  2018cites this paper
• Increased ARF6 activation correlates with HGF stimulation in non-invasive prostate cancer cells

  2018cites this paper
• Curcumin mediates reversion of HGF-induced epithelial-mesenchymal transition via inhibition of c-Met expression in DU145 cells.

  2016cites this paper
• Adenovirus expressing dual c-Met-specific shRNA exhibits potent antitumor effect through autophagic cell death accompanied by senescence-like phenotypes in glioblastoma cells

  2015cites this paper
• Targeting C-Met/VEGF in Castration Resistant Prostate Cancer

  2014cites this paper
• BASIS FOR TARGETING MET ACTIVATION MEDIATED RESISTANCE TO PI3K INHIBITION IN BREAST CANCER

  2013cites this paper
• Cabozantinib Inhibits Prostate Cancer Growth and Prevents Tumor-Induced Bone Lesions

  2013cites this paper
• Targeting c-MET in the battle against advanced nonsmall-cell lung cancer

  2013cites this paper
• Role of the MET–HGF axis in colorectal cancer: precepts and prospects

  2012cites this paper
• The role of PAK6 in HGF-induced prostate cancer cell migration

  2012cites this paper
• Emerging Clinical Applications and Pharmacology of RNA

  2012cites this paper
• Targeted therapies in metastatic castration-resistant prostate cancer: beyond the androgen receptor.

  2012cites this paper
• cMET and Phospho-cMET Protein Levels in Breast Cancers and Survival Outcomes

  2012cites this paper
• Development of c-MET pathway inhibitors

  2011cites this paper
• Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and survivin through suppressing specificity protein transcription factors.

  2011cites this paper
• HGF and RhoGTPases in Cancer Cell Motility

  2011cites this paper
• Targeting RhoC by Way of Ribozyme Trangene in Human Breast Cancer Cells and its Impact on Cancer Invasion

  2010cites this paper
• Effects of transferred NK4 gene on proliferation, migration, invasion and apoptosis of human prostate cancer DU145 cells.

  2010cites this paper
• Clinical implications of MET gene copy number in lung cancer.

  2010cites this paper
• HGF/SF up-regulates the expression of bone morphogenetic protein 7 in prostate cancer cells.

  2008cites this paper
• Phospholipase-C gamma-1 (PLCgamma-1) is critical in hepatocyte growth factor induced in vitro invasion and migration without affecting the growth of prostate cancer cells.

  2008cites this paper
• Targeting the c-MET signaling pathway for cancer therapy

  2008cites this paper
• Expression, regulation and roles of semaphorins and their receptors in prostate and prostate cancer.

  2008cites this paper
• Original article HGF/SF up-regulates the expression of bone morphogenetic protein 7 in prostate cancer cells

  2008cites this paper
• Membrane and membrane‐associated proteins involved in the aggressive phenotype displayed by highly invasive cancer cells

  2008cites this paper
• Targeting the c-MET signaling pathway for cancer therapy.

  2008cites this paper
• Predictive Value of Plasma Hepatocyte Growth Factor/Scatter Factor Levels in Patients with Clinically Localized Prostate Cancer

  2008cites this paper
• Co-Targeting Therapeutics for Hormone Refractory Prostate Cancer

  2007cites this paper
• Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and BMPR-II, in human prostate cancer cells.

  2007cites this paper
• Development of RNAi Libraries for Target Validation and Therapeutics

  2006cites this paper
• Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases

  2006cites this paper
• Pharmacology and Emerging Clinical Application of RNA

  2006cites this paper
• Specific and nontoxic silencing in mammalian cells with expressed long dsRNAs

  2006cites this paper
• Rho family GTPases are activated during HGF-stimulated prostate cancer-cell scattering.

  2005cites this paper
• Future therapies in hormone-refractory prostate cancer.

  2005cites this paper
• Hepatocyte growth factor/scatter factor and prostate cancer: a review.

  2005cites this paper
• Hepatocyte growth factor, its receptor, and their potential value in cancer therapies.

  2005cites this paper
• epithelial‑mesenchymal transition in oral cancer cells via c‑Met blockade

  year unknowncites this paper